Dong-A St (170900) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dong-A St (170900) has a cash flow conversion efficiency ratio of 0.003x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.99 Billion ≈ $1.35 Million USD) by net assets (₩671.65 Billion ≈ $455.17 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Dong-A St (170900) defensive interval to measure how many days the company can operate on defensive assets alone.
Dong-A St - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Dong-A St's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Dong-A St Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dong-A St ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
In Win Development Inc
TW:6117
|
0.006x |
|
Ocean Plastics Co Ltd
TW:1321
|
0.005x |
|
Wendell Industrial Co. Ltd
TWO:6761
|
0.048x |
|
Nucleus Software Exports Limited
NSE:NUCLEUS
|
0.137x |
|
Mastersystem Infotama Tbk.
JK:MSTI
|
-0.053x |
|
X3 Acquisition Corp. Ltd. Class A Ordinary Shares
NASDAQ:XCBE
|
-0.001x |
|
Dogan Burda Dergi Yayincilik ve Pazarlama AS
IS:DOBUR
|
0.164x |
|
TCI Express Limited
NSE:TCIEXP
|
0.026x |
Annual Cash Flow Conversion Efficiency for Dong-A St (2013–2025)
The table below shows the annual cash flow conversion efficiency of Dong-A St from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Dong-A St market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩671.65 Billion ≈ $455.17 Million |
₩27.78 Billion ≈ $18.83 Million |
0.041x | +348.74% |
| 2024-12-31 | ₩708.81 Billion ≈ $480.35 Million |
₩-11.79 Billion ≈ $-7.99 Million |
-0.017x | -436.74% |
| 2023-12-31 | ₩683.31 Billion ≈ $463.07 Million |
₩3.37 Billion ≈ $2.29 Million |
0.005x | -89.64% |
| 2022-12-31 | ₩690.11 Billion ≈ $467.68 Million |
₩32.89 Billion ≈ $22.29 Million |
0.048x | -36.63% |
| 2021-12-31 | ₩656.38 Billion ≈ $444.82 Million |
₩49.37 Billion ≈ $33.46 Million |
0.075x | +78.68% |
| 2020-12-31 | ₩642.10 Billion ≈ $435.14 Million |
₩27.03 Billion ≈ $18.32 Million |
0.042x | -51.67% |
| 2019-12-31 | ₩645.86 Billion ≈ $437.69 Million |
₩56.25 Billion ≈ $38.12 Million |
0.087x | +0.65% |
| 2018-12-31 | ₩579.36 Billion ≈ $392.63 Million |
₩50.14 Billion ≈ $33.98 Million |
0.087x | -1.83% |
| 2017-12-31 | ₩581.19 Billion ≈ $393.87 Million |
₩51.23 Billion ≈ $34.72 Million |
0.088x | +2648.88% |
| 2016-12-31 | ₩589.22 Billion ≈ $399.31 Million |
₩1.89 Billion ≈ $1.28 Million |
0.003x | -95.81% |
| 2015-12-31 | ₩553.77 Billion ≈ $375.28 Million |
₩42.40 Billion ≈ $28.73 Million |
0.077x | -55.88% |
| 2014-12-31 | ₩488.34 Billion ≈ $330.94 Million |
₩84.75 Billion ≈ $57.43 Million |
0.174x | +546.86% |
| 2013-12-31 | ₩439.36 Billion ≈ $297.75 Million |
₩-17.06 Billion ≈ $-11.56 Million |
-0.039x | -- |
About Dong-A St
Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Clofazimine cap. for lepromatous leprosy; Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bl… Read more